Seroatlas · Human Serome Atlas

PARP2

Poly [ADP-ribose] polymerase 2

Also known as: ADPRTL2, ARTD2, PARP2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UGN5
Gene
PARP2
Ensembl
ENSG00000129484
Chromosome
14
Canonical length
583 aa
Protein class
Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nucleoli

OverviewNCBI Gene

This gene encodes poly(ADP-ribosyl)transferase-like 2 protein, which contains a catalytic domain and is capable of catalyzing a poly(ADP-ribosyl)ation reaction. This protein has a catalytic domain which is homologous to that of poly (ADP-ribosyl) transferase, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly (ADP-ribosyl) transferase. The basic residues within the N-terminal region of this protein may bear potential DNA-binding properties, and may be involved in the nuclear and/or nucleolar targeting of the protein. Two alternatively spliced transcript variants encoding distinct isoforms have been found. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

583 residues, UniProt reviewed canonical sequence.

>Q9UGN5|PARP2
     1  MAARRRRSTG GGRARALNES KRVNNGNTAP EDSSPAKKTR RCQRQESKKM PVAGGKANKD
    61  RTEDKQDGMP GRSWASKRVS ESVKALLLKG KAPVDPECTA KVGKAHVYCE GNDVYDVMLN
   121  QTNLQFNNNK YYLIQLLEDD AQRNFSVWMR WGRVGKMGQH SLVACSGNLN KAKEIFQKKF
   181  LDKTKNNWED REKFEKVPGK YDMLQMDYAT NTQDEEETKK EESLKSPLKP ESQLDLRVQE
   241  LIKLICNVQA MEEMMMEMKY NTKKAPLGKL TVAQIKAGYQ SLKKIEDCIR AGQHGRALME
   301  ACNEFYTRIP HDFGLRTPPL IRTQKELSEK IQLLEALGDI EIAIKLVKTE LQSPEHPLDQ
   361  HYRNLHCALR PLDHESYEFK VISQYLQSTH APTHSDYTMT LLDLFEVEKD GEKEAFREDL
   421  HNRMLLWHGS RMSNWVGILS HGLRIAPPEA PITGYMFGKG IYFADMSSKS ANYCFASRLK
   481  NTGLLLLSEV ALGQCNELLE ANPKAEGLLQ GKHSTKGLGK MAPSSAHFVT LNGSTVPLGP
   541  ASDTGILNPD GYTLNYNEYI VYNPNQVRMR YLLKVQFNFL QLW

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PARP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
46 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 46 nTPM
  • cerebral cortex: 34 nTPM
  • skeletal muscle: 30 nTPM
  • basal ganglia: 26 nTPM
  • bone marrow: 25 nTPM
  • tongue: 25 nTPM

Single-cell type

  • differentiating spermatogonia: 61 nCPM
  • myonuclei: 45 nCPM
  • oocytes: 41 nCPM
  • erythrocyte progenitors: 36 nCPM
  • cytotrophoblasts: 35 nCPM
  • extravillous trophoblasts: 32 nCPM

Immune cell

  • MAIT T-cell: 12 nTPM
  • naive CD4 T-cell: 9 nTPM
  • gdT-cell: 8.9 nTPM
  • naive CD8 T-cell: 8.7 nTPM
  • memory CD4 T-cell: 8.4 nTPM
  • memory CD8 T-cell: 7.9 nTPM

Brain region

  • cerebral cortex: 25 nTPM
  • white matter: 21 nTPM
  • basal ganglia: 20 nTPM
  • cerebellum: 20 nTPM
  • hypothalamus: 19 nTPM
  • pons: 16 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.99
gnomAD pLI
0
gnomAD missense Z
0.49
DepMap mean gene effect
-0.08
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PARP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PARP2 as an antibody target. Whether an autoantibody or antibody against PARP2 could matter depends on whether native PARP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PARP2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PARP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PARP2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...